NU SKIN ENTERPRISES, INC. 8-K

What Happened
Nu Skin Enterprises, Inc. (NUS) reported that at its May 28, 2026 Annual Meeting stockholders approved an Amended and Restated 2024 Omnibus Incentive Plan, re-elected nine directors, gave advisory approval of executive compensation (say-on-pay), and ratified PricewaterhouseCoopers LLP as the company’s independent auditor for 2026. The company filed the 8‑K on May 29, 2026.

Key Details

• The Amended and Restated 2024 Omnibus Incentive Plan increases the share reserve by 2,850,000 shares and extends the plan term to the tenth anniversary of its effective date (May 28, 2036). Vote: For 24,185,333; Against 10,177,825; Abstain 40,483; Broker Non-Votes 5,430,258.
• Nine directors were elected to serve until the next annual meeting: Emma S. Battle; Daniel W. Campbell; Steven J. Lund; Ryan S. Napierski; Laura Nathanson; Thomas R. Pisano; James M. Winett; Edwina D. Woodbury; and Mark A. Zorko. Director vote totals varied by nominee (each received more than ~33.5M votes for).
• Advisory approval of executive compensation passed: For 33,111,458; Against 1,255,101; Abstain 37,082; Broker Non-Votes 5,430,258.
• Ratification of PricewaterhouseCoopers LLP as auditor passed: For 38,798,633; Against 970,082; Abstain 65,184.

Why It Matters
Approval of the amended incentive plan gives Nu Skin more shares and a longer window to grant equity awards, which management can use for employee and executive compensation, retention, and recruitment. Re-election of the board nominees and ratification of the auditor maintain governance continuity. The sizeable opposition on the incentive-plan vote (and the presence of ~5.43M broker non‑votes) are factual voting outcomes investors may monitor for governance and shareholder sentiment signals.